

Electronic Supplementary Material (ESI) for New Journal of Chemistry.

This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2020

## Supplementary Information

### Synthesis of 3-Oxadiazole-substituted imidazo[1,2-*a*]pyridines by Nickel Immobilized on Multifunctional Amphiphilic Porous Polysulfonamide-melamine

Sedigheh Alavinia, Ramin Ghorbani-Vaghei\*


Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, 65178/38695, Hamedan, Iran.

E-mail: [rgvaghei@yahoo.com](mailto:rgvaghei@yahoo.com)

#### Contents


1. Spectral data of all compounds 2-5
2. Spectra of all compounds 6-29

**2-(2-(naphthalen-2-yl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 282–284 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.56 (dd, *J* = 11.7, 7.4 Hz, 3H), 8.19 – 8.15 (m, 1H), 8.12 (dd, *J* = 8.6, 1.8 Hz, 1H), 8.00 (dd, *J* = 11.4, 8.3 Hz, 2H), 7.93 (d, *J* = 9.5 Hz, 1H), 7.71–7.59 (m, 3H), 7.59–7.44 (m, 3H), 7.28 (t, *J* = 6.7 Hz, 1H), 6.92 (t, *J* = 6.7 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.5, 145.4, 144.7, 133.7, 133.2, 133.1, 132.5, 131.9, 131.8, 129.8, 128.6, 128.5, 128.1, 127.4, 127.1, 126.8, 126.4, 125.5, 124.5, 124.5, 124.3, 123.8, 118.3, 117.1, 112.7, 110.1, 109.9; MS *m/z*: 388.4.

**2-(2-(3-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 269–270 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.84–8.87 (m, 1H), 8.11 (d, 2H), 7.94 (s, 2H), 7.58–7.65 (m, 4H), 7.46–7.52 (m, 3H), 7.10 (dq, *J* = 6.9, 2.2 Hz, 1H), 3.85 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 160.3, 140.6, 135.8, 133.9, 132.4, 131.2, 129.8, 129.5, 128.2, 127.1, 123.77, 118.8, 117.7, 116.4, 112.6, 112.0, 111.9, 55.9. MS *m/z*: 368.4.

**2-(2-(3-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid. M.p. 279–281 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.78 (s, 1H), 8.64 (m, 1H), 8.56 (d, *J* = 6.9 Hz, 1H), 8.40 (d, *J* = 7.8 Hz, 1H), 8.16 (t, *J* = 11 Hz, 3H), 7.75 (t, *J* = 8.2 Hz, 1H), 7.63–7.66 (m, 3H), 7.32 (t, *J* = 8.2 Hz, 1H), 6.96 (t, *J* = 6.9 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 148.8, 145.4, 142.3, 136.0, 132.5, 132.1, 130.8, 129.8, 127.6, 127.1, 126.2, 123.8, 122.6, 120.2, 117.2, 113.3, 111.0. MS *m/z*: 383.4. MS *m/z*: 383.1.

**2-phenyl-5-(2-(*p*-tolyl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 277–279 °C; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>) δ 8.51 (d, *J* = 6.8 Hz, 1H), 8.38–8.41 (m, 1H), 7.97 (dd, *J* = 10.5, 7.8 Hz, 3H), 7.56 (d, *J* = 9.1 Hz, 1H), 7.41 (d, *J* = 7.6 Hz, 4H), 7.31 (d, *J* = 7.1 Hz, 1H), 7.23 (t, *J* = 7.5 Hz, 1H), 6.87 (t, *J* = 7.5 Hz, 1H), 2.38 (s, 3H). <sup>13</sup>C NMR (63 MHz, DMSO-*d*<sub>6</sub>) δ 165.5, 142.5, 130.4, 129.1, 128.1, 127.3, 127.0, 125.9, 125.3, 121.0, 117.0, 112.7, 109.5, 21.5. MS *m/z*: 352.4.

**2-(2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a light pink solid, M.p. 240–242 °C; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>) δ 8.48 (s, 2H), 8.10 (s, 2H), 8.06–7.77 (m, 2H), 7.58 (s, 3H), 7.23–7.43 (m, 3H), 6.88 (s, 1H). <sup>13</sup>C NMR (63 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 145.3, 143.2, 136.5, 134.0, 132.4, 131.0, 129.8, 127.8, 127.4, 127.1, 125.7, 125.5, 124.5, 123.7, 117.1, 112.9, 110.4. MS *m/z*: 372.8.

**2-(2-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 326–328 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.90 (s, 1H), 8.81 (d, *J* = 6.8 Hz, 1H), 8.43 (d, *J* = 8.8 Hz, 1H), 8.23 (d, *J* = 8.7 Hz, 1H), 8.15 (dd, *J* = 7.3, 2.2 Hz, 2H), 7.87 (d, *J* = 10 Hz, 1H), 7.76 (t, *J* = 5 Hz, 1H), 7.63–7.69 (m, 4H), 7.34 (t, *J* = 6.8 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.5, 147.9, 132.5, 129.9, 129.0, 127.4, 127.1, 125.0, 123.8, 113.3. MS *m/z*: 383.4.

**2-phenyl-5-(2-(thiophen-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a dark orange solid. M.p. 330–332 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.49 (d, *J* = 6.8 Hz, 1H), 8.26 (s, 1H), 8.13 (d, *J* = 5 Hz, 2H), 7.69 – 7.58 (m, 2H), 7.59 – 7.44 (m, 3H), 7.23 (ddd, *J* = 8.8, 6.8, 1.4 Hz, 1H), 7.11 (dd, *J* = 5.1, 3.4 Hz, 1H), 6.88 (t, *J* = 6.8 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 144.9, 140.1, 138.2, 132.5, 129.8, 128.4, 127.2, 127.1, 125.9, 125.5, 124.0, 123.8, 116.7, 112.8, 108.6, MS *m/z*: 344.4.

**2-(2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 298–300 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.85 (d, *J* = 6.6 Hz, 1H), 8.68 (d, *J* = 4.0 Hz, 1H), 8.13 (d, *J* = 6.9 Hz, 3H), 7.89 (dd, *J* = 13.4, 6.2 Hz, 1H), 7.64 (d, *J* = 10 Hz, 6H), 7.16 (d, *J* = 8.2 Hz, 1H), 3.84 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 161.2, 140.5, 136.4, 133.1, 132.5, 129.8, 129.2, 128.1, 127.1, 123.8, 117.4, 115.3, 112.5, 110.4, 55.9. MS *m/z*: 368.2.

**2-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 302–305 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.57 – 8.46 (d, *J* = 5 Hz, 1H), 8.44 (s, 1H), 8.15 (dd, *J* = 5, 10 Hz, 2H), 7.98 (d, 2H), 7.72 – 7.63 (m, 3H), 7.59 (d, *J* = 9.1 Hz, 1H), 7.50 (d, *J* = 10 Hz, 2H), 7.27 (ddd, *J* = 8.6, 6.8, 1.5 Hz, 1H), 6.92 (t, *J* = 6.7 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.5, 133.2, 132.5, 132.5, 129.8, 129.2, 127.7, 127.4, 127.1, 125.7, 123.8, 117.1, 112.9, 109.9. MS *m/z*: 372.8.

**2-(2-(4-bromophenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.**




The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 290–292 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.93 – 8.81 (m, 2H), 8.13 (d, *J* = 10 Hz, 2H), 7.95 (d, *J* = 4.0 Hz, 1H), 7.92 – 7.80 (dd, *J* = 10, 12 Hz, 3H), 7.70– 7.60 (m, 4H), 7.54 – 7.46 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 140.9, 135.3, 133.8, 132.9, 132.5, 129.8, 129.5, 128.5, 127.1, 126.5, 124.1, 123.8, 117.6, 112.8, 112.1. MS *m/z*: 417.2.

### 2-(2-(2-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-5-phenyl-1,3,4-oxadiazole.



The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 10:5) gave the desired product as a white solid, M.p. 284–285 °C; <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 8.89 (d, *J* = 6.7 Hz, 1H), 8.44 (s, 1H), 8.22 (d, *J* = 10 Hz, 1H), 8.13 (d, *J* = 5.0 Hz, 3H), 8.03 (t, *J* = 10 Hz, 1H), 7.68 – 7.57 (m, 4H), 7.55 (s, 1H), 7.00 (s, 1H), 3.92 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 148.3, 146.3, 140.0, 138.3, 133.5, 132.5, 129.9, 129.4, 127.1, 123.8, 121.7, 117.8, 117.2, 116.6, 116.2, 113.0, 112.2, 111.9, 32.6. MS *m/z*: 369.0.

### 2-phenyl-5-(2-phenylimidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazole.



The general procedure was followed. Purification by column chromatography (silica gel, *n*-hexan/EtOAc, 5:1) gave the desired product as a white solid, M.p. 279–281 °C; <sup>1</sup>H NMR (250 MHz, DMSO-*d*<sub>6</sub>) δ 8.51 (d, *J* = 7.5 Hz, 1H), 8.37 (d, *J* = 4.1 Hz, 1H), 8.19 – 8.04 (m, 2H), 7.95 (d, *J* = 7.5 Hz, 2H), 7.54–7.63 (m, 3H), 7.49 – 7.34 (m, 2H), 7.25 (dt, *J* = 21.8, 7.2 Hz, 2H), 6.99 – 6.74 (m, 1H). <sup>13</sup>C NMR (63 MHz, DMSO-*d*<sub>6</sub>) δ 164.4, 145.2, 144.7, 134.3, 132.5, 129.8, 129.1, 128.1, 127.3, 127.1, 126.0, 125.3, 123.7, 117.0, 112.7, 109.5. MS *m/z*: 338.3.

